Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

Current Oncology Reports

Volumn 18, Issue 12, 2016, Pages

  García, Jorge ^a   Santomé, Lucia ^b   Anido, Urbano ^a   Fernández Calvo, Ovidio ^c   Afonso Afonso, Javier ^d   Lázaro, Martín ^e   Medina, Ana ^f   Vázquez Estévez, Sergio ^g  

^a University Hospital of Santiago de Compostela   (Spain)

^b HOSPITAL POVISA   (Spain)

^c University Hospital of Ourense   (Spain)

^d Universidad de La Coruña   (Spain)

^e Alvaro Cunqueiro Hospital   (Spain)

^f Regional Cancer Center of Galicia   (Spain)

^g University Hospital Lucus Augusti   (Spain)

Author keywords

Bladder cancer; Prognostic factors; Second line treatment; Vinflunine

Indexed keywords

AFATINIB; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BUPARLISIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACTOLISIB; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; GEFITINIB; GEMCITABINE; IFOSFAMIDE; INFIGRATINIB; LAPATINIB; METHOTREXATE; NEDAPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; SAPANISERTIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VINBLASTINE; VINFLUNINE; ANTINEOPLASTIC AGENT;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; KIDNEY FAILURE; LIVER FAILURE; LONG TERM SURVIVAL; MICROTUBULE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CLINICAL TRIAL (TOPIC); MOLECULARLY TARGETED THERAPY; PRACTICE GUIDELINE; PROGNOSIS; SECONDARY; STANDARDS; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84994301871     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-016-0556-3     Document Type: Review

References (84)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.
2. Kogevinas M, Mannetje AT, Cordier S, Ranft U, González CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control. 2003;14(10):907–14.
3. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009;3(6-S4):193–8.
4. Blick C, Hall P, Pwint T, Al‐Terkait F, Crew J, Powles T, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder. Cancer. 2012;118(16):3920–7.
5. Sternberg C, De Mulder P, Schornagel J, Theodore C, Fossa S, Van Oosterom A, et al. Randomized phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol. 2001;19(10):2638–46.
6. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8.
7. Loehrer P, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066–73.
8. Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107–13.
9. Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134–41.
10. Bennouna J, Fumoleau P, Armand J-P, Raymond E, Campone M, Delgado F-M, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol. 2003;14(4):630–7.
11. Johnson P, Geldart T, Fumoleau P, Pinel M-C, Nguyen L, Judson I. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs. 2006;24(3):223–31.
12. Zhao X-P, Zhong J, Liu X-Q, Wang G-J. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. Acta Pharmacol Sin. 2007;28(1):118–24.
13. Focan C, Van Heugen J, Kreutz F, Leroy I, De Graeve J, Blanchot G et al., editors. Vinflunine metabolism and disposition in cancer patients. Proc Am Soc Clin Oncol; 2002. p. 124a (Abstract 495).
14. Aparicio LMA, Pulido EG, Gallego GA. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs. 2012;23(1):1–11.
15. Aparicio LA, Castosa R, Haz-Conde M, Rodríguez M, Blanco M, Valladares M, et al. Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells. BMC Cancer. 2014;14(1):507.
16. Kruczynski A, Barret J-M, Etiévant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998;55(5):635–48.
17. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000;60(18):5045–51.
18. Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006;42(16):2821–32.
19. Holwell S, Hill B, Bibby M. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer. 2001;84(2):290.
20. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15(5):1853–7.
21. Papamichael D, Gallagher C, Oliver R, Johnson P, Waxman J. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer. 1997;75(4):606.
22. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002;20(4):937–40.
23. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24(21):3451–7.
24. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007;25(3):265–70.
25. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010;11(9):861–70.
26. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006;94(10):1395–401.
27. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, et al. Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinoma. Cancer. 2009;115(18):4110–7.
28. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61.
29. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81.
30. • Bellmunt J, Fougeray R, Rosenberg J, Von der Maase H, Schutz F, Salhi Y, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24(6):1466–72. The updated OS data confirm the positive treatment effect of vinflunine on survival that was previously reported.
31. Culine S, Lucas C, Salhi Y, Bellmunt J. Updated survival results of the phase III trial comparing vinflunine (V) to best supportive care (BSC) in advanced transitional cell carcinoma of the urothelium (TCC) after failure of a prior platinum-containing regimen. Eur Urol Suppl. 2010;9(2):38.
32. Tourani J, Mourey L, Servent V, Nguyen T, Ravaud A, Girre V, et al. Influence of age on the pharmacokinetics of iv vinflunine: results of a phase I trial in elderly cancer patients. J Geriatr Oncol. 2012;3(1):41–8.
33. Medioni J, Guillot A, Spaeth D, Di Palma M, Theodore C. Historical data in real life from patients treated by vinflunine for an advanced or metastatic urothelial carcinoma: results of the CURVE study. BMC Cancer. 2016;16(1):217.
34. Hegele A, Goebell P, Matz U, Neuhaus T. Monotherapy with intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: a retrospective analysis of German routine data. Urol Int. 2013;92(2):174–9.
35. Castellano D, Puente J, de Velasco G, Chirivella I, López-Criado P, Mohedano N, et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014;14(1):1.
36. Isambert N, Delord JP, Tourani JM, Fumoleau P, Ravaud A, Pinel MC, et al. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. Br J Clin Pharmacol. 2014;77(3):498–508.
37. Delord J, Ravaud A, Bennouna J, Fumoleau P, Favrel S, Pinel M, et al. Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. Invest New Drugs. 2013;31(3):724–33.
38. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–5.
39. Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013;63(4):717–23.
40. Harshman L, Fougeray R, Choueiri T, Schutz F, Salhi Y, Rosenberg J, et al. The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. Br J Cancer. 2013;109(10):2548–53.
41. Pond G, Bellmunt J, Rosenberg J, Bajorin D, Regazzi A, Choueiri T, et al. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015;13(1):71–9.
42. Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, et al. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015;13(2):185–92.
43. Krajewski KM, Fougeray R, Bellmunt J, Pons F, Schutz FA, Rosenberg JE, et al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 2012;48(10):1495–502.
44. Kitamura H, Taguchi K, Kunishima Y, Yanase M, Takahashi A, Shigyo M, et al. Paclitaxel, ifosfamide, and nedaplatin as second‐line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group. Cancer Sci. 2011;102(6):1171–5.
45. Han K, Joung J, Kim T, Jeong I, Seo H, Chung J, et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer. 2008;98(1):86–90.
46. Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol. 2007;52(4):1115–22.
47. Srinivas S, Harshman LC. A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. Chemotherapy. 2009;55(5):321–6.
48. Joung JY, Kwon WA, Cho IC, Kim EK, Park S, Yoon H, et al. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum‐based regimens. Int J Urol. 2011;18(5):350–7.
49. Edeline J, Loriot Y, Culine S, Massard C, Albiges L, Blesius A, et al. Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum–gemcitabine regimen. Eur J Cancer. 2012;48(8):1141–6.
50. Joly F, Houédé N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, et al. Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer. 2009;7(2):E28–33.
51. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy. Cancer. 2001;92(12):2993–299.
52. Kanai K, Kikuchi E, Ohigashi T, Miyajima A, Nakagawa K, Nakashima J, et al. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol. 2008;13(6):510–4.
53. Fechner G, Siener R, Reimann M, Kobalz L, Albers P. Randomised phase II trial of gemcitabine and paclitaxel second‐line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60(1):27–31.
54. Albers P, Park S-I, Niegisch G, Fechner G, Steiner U, Lehmann J, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 2011;22(2):288–94.
55. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Evan YY, Quinn DI, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012;30(5):507–12.
56. Ko Y-J, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013;14(8):769–76.
57. Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997;15(2):589–93.
58. Lorusso V, Pollera C, Antimi M, Luporini G, Gridelli C, Frassineti G, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer. 1998;34(8):1208–12.
59. Gebbia V, Testa A, Borsellino N, Mauceri G, Varvara F, Tirrito M, et al. Single agent 2′, 2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter. 1998;150(1):11–5.
60. Albers P, Siener R, Härtlein M, Fallahi M, Haeutle D, Perabo F, et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma—prognostic factors for response and improvement of quality of life. Onkologie. 2002;25(1):47–52.
61. Akaza H, Naito S, Usami M, Miki T, Miyanaga N, Taniai H. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience. Jpn J Clin Oncol. 2007;37(3):201–6.
62. Benjamin DJ, Bambury RM, Chaim J, Zabor EC, Ostrovnaya I, Garcia-Grossman IR, et al. Efficacy of single-agent pemetrexed in platinum refractory metastatic urothelial cancer (mUC). ASCO Annu Meet Proc. 2014;32(4 suppl):322.
63. •• Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65. Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clinical outcomes and responses to conventional chemotherapy. In this study, three molecular subtypes of MIBC are identified and these have important implications for prognostication, the future clinical development of targeted agents, and disease management with conventional chemotherapy.
64. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci. 2014;111(8):3110–5.
65. Network CGAR. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.
66. Guancial EA, Rosenberg JE. The role of genomics in the management of advanced bladder cancer. Curr Treat Options Oncol. 2015;16(1):1–15.
67. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev. 2015;41(2):170–8.
68. Moon DG, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol. 2014;45(3):1027–35.
69. Milowsky MI, Iyer G, Regazzi AM, Al‐Ahmadie H, Gerst SR, Ostrovnaya I, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112(4):462–70.
70. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15(19):6008–17.
71. García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res. 2012;18(9):2603–12.
72. Wong Y-N, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30(28):3545–51.
73. Petrylak DP, Tangen CM, Van Veldhuizen PJ, Goodwin JW, Twardowski PW, Atkins JN, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010;105(3):317–21.
74. Wülfing C, Machiels JPH, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115(13):2881–90.
75. Culine S, Sellam Z, Bouaita L, Assaf E, Delbaldo C, Verlinde-Carvalho M, et al. Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series. Anticancer Res. 2012;32(9):3949–52.
76. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25(16):2218–24.
77. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer. Cancer. 2009;115(18):4090–5.
78. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010;28(8):1373–9.
79. Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancer Oncol. 2012;13(8):810–6.
80. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, et al. Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010;76(4):923–6.
81. Acquaviva J, He S, Zhang C, Jimenez J-P, Nagai M, Sang J, et al. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. Mol Cancer Res. 2014;12(7):1042–54.
82. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.
83. •• Rosemberg JE, Hoffman-Censits C, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase II trial. Lancet. 2016;387:1909–20. Atezolizumab showed durable activity and good tolerability in patients with advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy. This study show the association of TCGA subtypes with response to immune checkpoint inhibition.
84. Plimack ER, Bellmunt J, Gupta S, Berger R, Montgomery RB, Heath K et al., editors. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. ASCO Annual Meeting Proceedings; 2015.